Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells

被引:30
作者
Do, Hyo-Sang [1 ]
Park, Sang-Wook [1 ,2 ]
Im, Ilkyun [3 ]
Seo, Donghyuk [1 ]
Yoo, Han-Wook [4 ]
Go, Heounjeong [5 ]
Kim, Yoo Hyung [6 ,8 ]
Koh, Gou Young [7 ,8 ]
Lee, Beom-Hee [4 ]
Han, Yong-Mahn [1 ]
机构
[1] Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon 34141, South Korea
[2] Daegu Gyeongbuk Med Innovat Fdn, New Drug Dev Ctr, Daegu 41061, South Korea
[3] Korea Inst Toxicol, Dept Predict Toxicol, Daejeon 34141, South Korea
[4] Univ Ulsan, Childrens Hosp, Asan Med Ctr, Dept Pediat,Coll Med, Seoul 05505, South Korea
[5] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Pathol, Seoul 05505, South Korea
[6] Korea Adv Inst Sci & Technol, Coll Nat Sci, Daejeon 34141, South Korea
[7] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon 34141, South Korea
[8] Inst for Basic Sci Korea, Ctr Vasc Res, Daejeon 34141, South Korea
来源
EBIOMEDICINE | 2020年 / 52卷
基金
新加坡国家研究基金会;
关键词
Fabry disease; Human induced pluripotent stem cells (hiPSCs); Globotriaosylceramide (Gb3); Vascular dysfunction; Thrombospondin-1; SIGNALING PATHWAYS; ENZYME REPLACEMENT; GROWTH-FACTOR; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; ALPHA-GALACTOSIDASE; ACTIVATION; MECHANISMS; EXPRESSION; RESPONSES;
D O I
10.1016/j.ebiom.2020.102633
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fabry disease (FD) is a recessive X-linked lysosomal storage disorder caused by alpha-galactosidase A (GLA) deficiency. Although the mechanism is unclear, GLA deficiency causes an accumulation of globotriaosylceramide (Gb3), leading to vasculopathy. Methods: To explore the relationship between the accumulation of Gb3 and vasculopathy, induced pluripotent stem cells generated from four Fabry patients (FD-iPSCs) were differentiated into vascular endothelial cells (VECs). Genome editing using CRISPR-Cas9 system was carried out to correct the GLA mutation or to delete Thrombospondin-1 (TSP-1). Global transcriptomes were compared between wild-type (WT)- and FD-VECs by RNA-sequencing analysis. Findings: Here, we report that overexpression of TSP-1 contributes to the dysfunction of VECs in FD. VECs originating from FD-iPSCs (FD-VECs) showed aberrant angiogenic functionality even upon treatment with recombinant alpha-galactosidase. Intriguingly, FD-VECs produced more p-SMAD2 and TSP-1 than WT-VECs. We also found elevated TSP-1 in the peritubular capillaries of renal tissues biopsied from FD patients. Inhibition of SMAD2 signaling or knock out of TSP-1 (TSP-1(-/-)) rescues normal vascular functionality in FD-VECs, like in gene-corrected FD-VECs. In addition, the enhanced oxygen consumption rate is reduced in TSP-1(-/-) FD-VECs. Interpretation: The overexpression of TSP-1 secondary to Gb3 accumulation is primarily responsible for the observed FD-VEC dysfunction. Our findings implicate dysfunctional VEC angiogenesis in the peritubular capillaries in some of the complications of Fabry disease. (C) 2020 The Author(s). Published by Elsevier B.V.
引用
收藏
页数:15
相关论文
共 59 条
  • [11] FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition
    Cross, MJ
    Claesson-Welsh, L
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (04) : 201 - 207
  • [12] Thrombospondin-1 is a major activator of TGF-β in fibrotic renal disease in the rat in vivo
    Daniel, C
    Wiede, J
    Krutzsch, HC
    Ribeiro, SMF
    Roberts, DD
    Murphy-Ullrich, JE
    Hugo, C
    [J]. KIDNEY INTERNATIONAL, 2004, 65 (02) : 459 - 468
  • [13] Desnick RJ., 2014, The Online Metabolic and Molecular Bases of Inherited Disease
  • [14] CARDIOCYTE STORAGE AND HYPERTROPHY AS A SOLE MANIFESTATION OF FABRYS-DISEASE - REPORT ON A CASE SIMULATING HYPERTROPHIC NONOBSTRUCTIVE CARDIOMYOPATHY
    ELLEDER, M
    BRADOVA, V
    SMID, F
    BUDESINSKY, M
    HARZER, K
    KUSTERMANNKUHN, B
    LEDVINOVA, J
    BELOHLAVEK
    KRAL, V
    DORAZILOVA, V
    [J]. VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1990, 417 (05) : 449 - 455
  • [15] A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies
    Eng, CM
    Banikazemi, M
    Gordon, RE
    Goldman, M
    Phelps, R
    Kim, L
    Gass, A
    Winston, J
    Dikman, S
    Fallon, JT
    Brodie, S
    Stacy, CB
    Mehta, D
    Parsons, R
    Norton, K
    O'Callaghan, M
    Desnick, RJ
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (03) : 711 - 722
  • [16] Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
    Eng, CM
    Guffon, N
    Wilcox, WR
    Germain, DP
    Lee, P
    Waldek, S
    Caplan, L
    Linthorst, GE
    Desnick, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) : 9 - 16
  • [17] Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
    Gale, NW
    Yancopoulos, GD
    [J]. GENES & DEVELOPMENT, 1999, 13 (09) : 1055 - 1066
  • [18] Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis
    Gupta K.
    Gupta P.
    Wild R.
    Ramakrishnan S.
    Hebbel R.P.
    [J]. Angiogenesis, 1999, 3 (2) : 147 - 158
  • [19] Harry Lorraine E., 2003, Birth Defects Research, V69, P363, DOI 10.1002/bdrc.10024
  • [20] Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in mice
    Hayashi, Hiromitsu
    Sakai, Keiko
    Baba, Hideo
    Sakai, Takao
    [J]. HEPATOLOGY, 2012, 55 (05) : 1562 - 1573